Viking Therapeutics, Inc. 8K

Viking Therapeutics reported larger Q2 2026 losses driven by expanded R&D as it advances late‑stage obesity programs (notably VK2735) and initiates a Phase 1 trial of VK3019, while maintaining a $502 million cash position and adding senior leadership and board expertise.

On July 29, 2026, Viking Therapeutics, Inc. reported its second quarter and six‑month 2026 financial results, highlighting a substantial increase in R&D spending and a larger net loss as it advances its obesity pipeline, including fully enrolled Phase 3 VANQUISH‑1 and VANQUISH‑2 trials of subcutaneous VK2735, preparations to initiate Phase 3 studies of an oral VK2735 formulation in 4Q26, an ongoing VK2735 maintenance dosing Phase 1 study with data expected in 3Q26, and the initiation of a Phase 1 SAD trial of amylin agonist VK3019, while also announcing key leadership additions and ending the quarter with $502 million in cash, cash equivalents and short‑term investments.

Filing Facts

CIK

1607678

Ticker

VKTX

Form

8K

Source Type

fda

Accession

0001193125-26-323652

Alert Tier

6